Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

Overview of attention for article published in OncoTargets and therapy, October 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

twitter: 4 X users

patent: 2 patents

Citations

dimensions_citation: 194 Dimensions

Readers on

mendeley: 207 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

COMBINATION OF T-CELL THERAPY AND TARGETED THERAPY FOR TREATING THERAPY-RESISTANT…

Application WO-2020168047-A1

World Intellectual Property Organisation (WIPO)

METHOD FOR PREDICTING THE RESISTANCE OF MELANOMA TO A TREATMENT WITH A BRAF INHIBITOR

Application EP-3696545-A1

European Patent Office